NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
The Toads Didn’t Consent to Being Milked, Sorry
Chasing "enlightenment" at the expense of desert toads is not the flex you think it is. [...] Read More... The post The Toads Didn’t Consent to Being Milked, Sorry appeared first on DoubleBlind Mag.
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
TEL AVIV, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage…
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
NEW YORK, August 12, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics…
Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in special operations veterans with traumatic brain injuries
This 12-month follow-up study (n=25) of male US Special Operations Veterans with traumatic brain injury (TBI) found that reductions in disability, PTSD, depression and anxiety symptoms after a single magnesium-ibogain...
Exploring the interface of meditation and psychedelics: A qualitative analysis of experienced practitioners’ perspectives on psychedelic preparation
Exploring the interface of meditation and psychedelics: A qualitative analysis of experienced practitioners’ perspectives on psychedelic preparation
Opposite network patterns of integration-segregation in psychedelic and sedated states of consciousness
This brain imaging analysis used fMRI to compare brain network organisation across psychedelic states, sleep, and propofol sedation. Psychedelics increased communication between normally separate brain networks while ...
Real-world use, safety, and mental health efficacy of regulated psilocybin services in Oregon and Colorado
This retrospective observational study (n=2363) examined regulated psilocybin services in Oregon and Colorado, where most clients had pre-existing mental health issues. Two weeks after dosing, depression and anxiety s...
Psychedelic Medicine Is Having an Identity Crisis — And That’s a Good Thing
For most of the last decade, the story of psychedelic medicine was a story about the trip itself. Guided sessions. Eyeshades and headphones. A therapist sitting with a patient for six or eight hours while a single dos...
Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High
Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On August 5, 2026, the...
A free, continuously updated guide to bipolar disorder treatments
The most comprehensive review to date has identified the most effective bipolar disorder treatments across different age groups and mood phases. It was published in The BMJ.
Weekly Psychedelic Policy Briefing – August 9, 2026
Jack Gorsline, investigative journalist, covers four federal developments this week. The Department of Veterans Affairs launched a five-site psilocybin trial, and the drug it runs on belongs to a company preparing an ...
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an August 9 report by Psychedelic Alpha indicating that Resilient Pharmaceuticals (formerly MAPS PBC and...
Why don’t some people respond to psychedelics? 5 Questions for psychologist Rachel Ham
Ham discusses doing interviews with clinical trial participants who didn’t experience substantial benefits.
Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?
MAPS co-executive director Ismail Lourido Ali on what the April 2026 executive order, the Texas and Colorado funding fights, and Gabon's new iboga decree mean for who gets access to ibogaine and who benefits from it. ...
A fast-acting psychedelic shows promise for postpartum depression
A new clinical trial suggests that a single day of treatment with the inhaled psychedelic mebufotenin can rapidly relieve severe symptoms of postpartum depression, offering a potential alternative to daily medications.